Genfleet Therapeutics (Shanghai), Inc. Class H (2595) Stock Price & Analysis
2595 Stock Chart & Stats
- Day’s Range
- HKD 22.50 - HKD 25.48
- 52-Week Range
- HKD 19.60 - HKD 52.90
- Previous Close
- HKD 24.96
- Volume
- N/A
- Average Volume (3M)
- 4.54M
- Market Cap
- HKD 8.64B
- Enterprise Value
- HKD 9.00B
- Total Cash (Recent Filing)
- N/A
- Total Debt (Recent Filing)
- N/A
- Price to Earnings (P/E)
- ―
- Beta
- 1.09
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Genfleet Therapeutics (Shanghai), Inc. Class H News
GenFleet Reveals GFH375 Combo Added to Proposed Breakthrough Therapy List After Share Price Surge
Genfleet Therapeutics (Shanghai), Inc. Class H ( ($HK:2595) ) just unveiled an announcement. GenFleet Therapeutics disclosed that its clinical program evaluating GFH375 combined with cetuximab has been placed on the
GenFleet Advances 2026 H-Share Buyback With Initial Repurchases
Genfleet Therapeutics (Shanghai), Inc. Class H ( ($HK:2595) ) has issued an announcement. GenFleet Therapeutics (Shanghai), Inc., a Hong Kong-listed biopharmaceutical company specializing in innovative therapeutics, operates under a diversified
GenFleet’s KRAS G12D Lung Cancer Drug Shows Strong Phase II Results, Advancing to First Global Phase III Trial
The latest announcement is out from Genfleet Therapeutics (Shanghai), Inc. Class H ( ($HK:2595) ). GenFleet Therapeutics reported updated Phase II results for its oral KRAS G12D inhibitor GFH375 in
GenFleet Advances KRAS G12D Lung Cancer Drug GFH375 into First-Line Phase II Study
The latest update is out from Genfleet Therapeutics (Shanghai), Inc. Class H ( ($HK:2595) ). GenFleet Therapeutics (Shanghai) Inc., a China-based oncology drug developer, is advancing GFH375, its orally active,
2595 FAQ
What was Genfleet Therapeutics (Shanghai), Inc. Class H’s price range in the past 12 months?
What is Genfleet Therapeutics (Shanghai), Inc. Class H’s market cap?
When is Genfleet Therapeutics (Shanghai), Inc. Class H’s upcoming earnings report date?
How were Genfleet Therapeutics (Shanghai), Inc. Class H’s earnings last quarter?
Is Genfleet Therapeutics (Shanghai), Inc. Class H overvalued?
Does Genfleet Therapeutics (Shanghai), Inc. Class H pay dividends?
What is Genfleet Therapeutics (Shanghai), Inc. Class H’s EPS estimate?
How many shares outstanding does Genfleet Therapeutics (Shanghai), Inc. Class H have?
What happened to Genfleet Therapeutics (Shanghai), Inc. Class H’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Genfleet Therapeutics (Shanghai), Inc. Class H?
What is the TipRanks Smart Score and how is it calculated?
Genfleet Therapeutics (Shanghai), Inc. Class H Stock Smart Score
Company Description
Genfleet Therapeutics (Shanghai), Inc. Class H
GenFleet Therapeutics (Shanghai) Inc., a biopharmaceutical company, develops treatment options in the fields of oncology, autoimmune, and inflammatory diseases in the United States. The company develops GFH375, an orally bioavailable small molecule inhibitor of Kirsten rat sarcoma (KRAS) G12C in a Phase III trial for the treatment of pancreatic cancer, as well as in Phase II trials for the treatment of non-small cell lung cancer (NSCLC) and BTC, and in a Phase I trial for the treatment of solid tumors; GFH925, a small molecule selective inhibitor of KRAS G12C in a Phase II trial for the treatment of advanced NSCLC; and GFH009, a highly selective cyclin-dependent kinase (CDK) 9 inhibitor in a Phase II trial for the treatment of AML. It is also developing GFH276, a pan-RAS inhibitor in a Phase I trial for the treatment of solid tumors; GFS202A, a bispecific antibody in a Phase I trial for the treatment of cachexia; GFH312, a receptor-interacting serine/threonine-protein kinase (RIPK) 1 inhibitor in a Phase I clinical trial for the treatment of PAD with IC and PBC; GFS784, a pan-RAS antibody drug conjugate (ADC) candidate with an IND application for the treatment of solid tumors; and GFH946, an oral PROTAC product candidate with an IND application for the treatment of type 2 inflammation. In addition, the company offers technical services. It has collaboration agreements with Merck Healthcare KGaA for trials of combinational regimens, including cetuximab; Verastem, Inc. to develop and commercialize GFH375; and SELLAS Life Sciences Group, Inc. to develop, manufacture, and commercialize GFH009. GenFleet Therapeutics (Shanghai) Inc. was incorporated in 2017 and is headquartered in Shanghai, China.
- Sector
- General
- Industry
- Biotechnology
- CEO
- Jiong Lan
- Employees
- 159
- Website
- www.genfleet.com
- Address
- Building 8 Floors 2, Shanghai, SH, 201203, CN
Genfleet Therapeutics (Shanghai), Inc. Class H (2595) Earnings & Revenues
2595 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 2 | 14 |
| Technical Analysis | 6 | 2 | 2 |
| Moving Averages | 0 | 0 | 12 |





